Clinical trial
Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in…
NCT00331552 · University of Washington, Other · Completed
Key facts
| NCT number | NCT00331552 |
|---|---|
| Title | Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer |
| Official title | Phase I - II Study of Doxil® In Combination With Daily Oral Cyclophosphamide and Herceptin for Patients With HER-2/Neu Positive Disease In Patients With Metastatic Breast Cancer |
| Lead sponsor | University of Washington, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | pegylated liposomal doxorubicin hydrochloride, cyclophosphamide, trastuzumab |
| Enrollment | 30 |
| Start date | Feb 1, 2006 |
| Primary completion | Feb 1, 2011 |
| Completion | Feb 1, 2012 |
| First posted | May 31, 2006 |
| Last update posted | Jul 26, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: